Pierre-Louis Mikus joins as chief legal officer; Bertrand Waymel is promoted to group human resources director
- Swift execution of ‘Back to Basics’ strategic plan leading to successful portfolio reshaping
- All business units contributing to the strong performance
- 20% EBITDA growth driven by focus on attractive projects and cost control policy
Pompey, France, and San Diego, CA, USA, March 24, 2015 - Novasep, a leading supplier of services and technologies for the life sciences and chemical industries and Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.
Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that it has entered into an agreement with Celladon, a clinical-stage biotechnology company. Novasep will prepare to supply the drug substance for MYDICAR®.
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Novasep Varicol high-performance continuous chromatography technology brings productivity gains in an Indian-based API commercial production.
Novasep wins approval to produce new molecular entity for US market.
The plant will enable Vietnam to domestically produce sorbitol, a sugar substitute it currently imports.
The new Highly Potent API (HPAPI) manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.